The board at pharmaceutical company Bristol-Myers Squibb scored high on age dispersion, and for having a high number of senior independent nonexecutive directors. Bristol-Myers Squibb’s board has three current CEOs, including its own, Giovanni Caforio, and Peter Arduini, CEO of GE Healthcare. Also on the board is Derica Rice, former CVS Health EVP and president of CVS Caremark, the pharmacy benefits management (PBM) business. Though the company is facing a patent cliff, analysts are optimistic that BMS’s strong pipeline and cash flow will help carry the company in the long run. In 2021 BMS brought in $46.4 billion in revenue, exceeding its annual target and registering 9% year-on-year growth. The company also reported strong performance on supply-chain reliability and COVID-19 response, with a 99% vaccination rate among its employees in the U.S. and Puerto Rico. BMS published its first global diversity and inclusion report in 2021, setting goals to achieve gender parity at the executive level globally and to double the number of Black and Latinx/Hispanic executives in the U.S. by the end of 2022. BMS plans to leverage up to $45 billion in free cash flow in the next two years to execute a capital allocation strategy prioritizing business development and returns to shareholders. The company recently executed a $5 billion accelerated share repurchase agreement during the first quarter, part of a multiyear $15 billion buyback program.
|Headquarters||New York City|
|No. of employees||32,200|